Tesamorelin vs SS-31

Tesamorelin and SS-31 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH). It holds the distinction of being the only FDA-approved medication for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, marketed under the brand name Egrifta. By stimulating the endogenous production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), Tesamorelin effectively reduces visceral adipose tissue. The recent FDA approval of Egrifta WR, a weekly-reconstitution formulation, further expands its clinical utility. Phase 3 clinical trials have demonstrated significant reductions in visceral fat over a 26-week treatment period, with results indicating a generally well-tolerated safety profile. Notably, the efficacy of Tesamorelin extends to individuals on integrase strand transfer inhibitor (INSTI)-based HIV regimens, reinforcing its relevance in this patient population.

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that exhibits a unique mechanism by selectively accumulating in the inner mitochondrial membrane. This peptide binds to cardiolipin, a phospholipid crucial for mitochondrial function, thereby stabilizing the cristae structure and promoting mitochondrial integrity. SS-31 is currently under development by Stealth BioTherapeutics for various indications, including mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. The peptide has been evaluated in multiple Phase I to III clinical trials, including the TAZPOWER trial, which specifically investigates its effects in Barth syndrome. Research suggests that SS-31 may enhance mitochondrial function, reduce cardiac dysfunction, and potentially exhibit anti-aging properties, although the complete clinical implications are still under investigation.

While Tesamorelin and SS-31 are both studied in the context of health and disease, they target markedly different research applications. Tesamorelin is primarily investigated for its role in body composition, particularly in the context of HIV-associated lipodystrophy, where it serves to mitigate visceral fat accumulation. Conversely, SS-31 is being explored for its potential in anti-aging interventions and metabolic health, particularly through its effects on mitochondrial function. The divergence in their applications reflects the distinct biological pathways they modulate, highlighting the importance of selecting the appropriate peptide based on the specific research focus.

Safety profiles for Tesamorelin and SS-31 reveal important considerations for researchers. In clinical settings, Tesamorelin has been associated with mild adverse effects, including headache, nausea, and flu-like symptoms. It may also lead to increased blood glucose levels, necessitating monitoring in diabetic patients. The FDA categorizes Tesamorelin as pregnancy category X, indicating potential risks for fetal development. In contrast, SS-31 has demonstrated a favorable safety profile in clinical trials, with mild adverse effects such as headache, dizziness, and nausea reported. Importantly, no significant safety signals have emerged from Phase I and II trials, suggesting a generally well-tolerated profile at tested doses.